RxDoctor Payments DataLook up a doctor →

Vinay Nagaraj, MD

Addiction Psychiatry · Suwanee, GANPI 1952585424

Payments from drug & device makers

$9,254in general payments, 2019–2025

Across 563 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Johnson & Johnson$1K
  • Alkermes, Inc.$838
  • Lundbeck LLC$600
  • Otsuka America Pharmaceutical, Inc.$597
  • plus $4K from 23 others

What the payments were for

  • Food & beverage$9,222100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,254 in reported general payments places this provider in the 95th percentile of 22 addiction psychiatry providers in Georgia.

See all addiction psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$60,564
Medicare patients
72
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide15$11,356
Aripiprazole47$9,874
Adderall XrDextroamphetamine/Amphetamine12$5,043
AzstarysSerdexmethylphen/Dexmethylphen12$4,891
Atomoxetine Hcl11$3,234
Duloxetine Hcl73$2,803
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine31$1,698
Ziprasidone Hcl23$1,364
Buspirone Hcl62$1,352
Venlafaxine Hcl ErVenlafaxine Hcl31$1,346
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,327
Doxepin Hcl23$1,237
Bupropion XlBupropion Hcl42$915
Gabapentin38$906
Fluvoxamine Maleate17$758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$418$11,35615 claims
Corium, LLCAzstarys$386$4,89112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 addiction psychiatry providers in Georgia.

Other addiction psychiatry in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →